Use of nonacog beta pegol during surgery in persons with hemophilia B: a case series.
factor IX
hemophilia B
hemostasis
surgery
surgical hemostasis
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
12
05
2022
revised:
11
08
2023
accepted:
03
09
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
epublish
Résumé
Hemophilia B is a coagulation disorder that puts patients at an increased risk of bleeding. Factor (F) IX replacement therapy is traditionally used in such cases to maintain hemostasis. Nonacog beta pegol (N9-GP; Refixia) is a glycoPEGylated, extended half-life, recombinant FIX product that has demonstrated safety and efficacy when used to manage persons with hemophilia B. Given the limited real-world evidence, we aimed to explore the role of N9-GP in maintaining hemostasis in persons with hemophilia B undergoing surgery. In this case series, we report real-world clinical experience with N9-GP to maintain hemostasis in persons with hemophilia B undergoing major and minor surgeries. The majority of cases presented in this case series had an excellent or very good hemostatic response, with no reported surgical complications related to the use of N9-GP.
Sections du résumé
Background
UNASSIGNED
Hemophilia B is a coagulation disorder that puts patients at an increased risk of bleeding. Factor (F) IX replacement therapy is traditionally used in such cases to maintain hemostasis. Nonacog beta pegol (N9-GP; Refixia) is a glycoPEGylated, extended half-life, recombinant FIX product that has demonstrated safety and efficacy when used to manage persons with hemophilia B.
Key clinical question
UNASSIGNED
Given the limited real-world evidence, we aimed to explore the role of N9-GP in maintaining hemostasis in persons with hemophilia B undergoing surgery.
Clinical approach
UNASSIGNED
In this case series, we report real-world clinical experience with N9-GP to maintain hemostasis in persons with hemophilia B undergoing major and minor surgeries.
Conclusion
UNASSIGNED
The majority of cases presented in this case series had an excellent or very good hemostatic response, with no reported surgical complications related to the use of N9-GP.
Identifiants
pubmed: 38077810
doi: 10.1016/j.rpth.2023.102208
pii: S2475-0379(23)00465-X
pmc: PMC10704488
doi:
Types de publication
Case Reports
Langues
eng
Pagination
102208Informations de copyright
© 2023 The Authors.
Références
Haemophilia. 2016 Jul;22(4):e259-66
pubmed: 27333467
Haemophilia. 2016 Jul;22(4):507-13
pubmed: 26936227
Int J Environ Res Public Health. 2019 Apr 17;16(8):
pubmed: 30999657
Thromb Res. 2016 May;141:69-76
pubmed: 26970716
Thromb Haemost. 2020 May;120(5):737-746
pubmed: 32369845
Res Pract Thromb Haemost. 2022 Mar 31;6(3):e12661
pubmed: 35386274
Haemophilia. 2017 Jan;23(1):67-76
pubmed: 27480487
Ther Adv Hematol. 2018 Sep 06;9(9):295-308
pubmed: 30210757
Res Pract Thromb Haemost. 2020 Jul 29;4(7):1101-1113
pubmed: 33134776
Haemophilia. 2020 Aug;26 Suppl 6:1-158
pubmed: 32744769
Blood. 2014 Dec 18;124(26):3880-6
pubmed: 25261199
Thromb Res. 2020 Apr;188:85-89
pubmed: 32109773